Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference

GlobeNewswire June 3, 2021

Ultragenyx to Present at Jefferies Virtual Healthcare Conference

GlobeNewswire May 26, 2021

GeneTx and Ultragenyx Receive Clearance from Health Canada to Begin Clinical Study of GTX-102 in Canada for the Treatment of Angelman Syndrome

GlobeNewswire May 19, 2021

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 18, 2021

Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual Meeting

GlobeNewswire May 14, 2021

Ultragenyx to Present at Bank of America Securities Healthcare Conference

GlobeNewswire May 10, 2021

Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update

GlobeNewswire May 4, 2021

Ultragenyx to Present at Truist Securities Life Sciences Summit

GlobeNewswire April 28, 2021

Ultragenyx to Host Conference Call for First Quarter 2021 Financial Results and Corporate Update

GlobeNewswire April 28, 2021

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting

GlobeNewswire April 27, 2021

Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy Program

GlobeNewswire April 22, 2021

n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases

Business Wire April 5, 2021

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III

GlobeNewswire March 8, 2021

Ultragenyx to Present at Barclays Global Healthcare Conference

GlobeNewswire March 3, 2021

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire February 17, 2021

Ultragenyx Announces Approval of Dojolvi(TM) (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

GlobeNewswire February 17, 2021

Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

GlobeNewswire February 11, 2021

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update

GlobeNewswire February 4, 2021

Sizing Up the Sectors and Going for Growth: The 28th Annual Emerald Groundhog Day Investment Forum Goes Live on February 4th

Business Wire February 2, 2021

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease

GlobeNewswire January 21, 2021